Trials / Completed
CompletedNCT01644825
Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer
MITO-11: A Randomized Multicentre Phase II Trial With Pazopanib and Weekly Paclitaxel vs Weekly Paclitaxel in Platinum Resistant or Refractory Ovarian Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- National Cancer Institute, Naples · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and activity of adding pazopanib to weekly chemotherapy with paclitaxel for patients with ovarian cancer that is resistant or refractory to treatment with platinum based therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | paclitaxel | 80 mg/m2 IV days 1, 8, 15 every 28 days |
| DRUG | pazopanib | orally, 800 mg orally daily |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2014-05-01
- Completion
- 2015-12-29
- First posted
- 2012-07-19
- Last updated
- 2018-04-09
Locations
20 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT01644825. Inclusion in this directory is not an endorsement.